Estradiol can suppress IL-17A production from neutrophils and macrophages, which express estrogen receptors, resulting in psoriasis clinical phenotypes by sex-dependent differences, indicating that sex differences make the side effect risk of IL-23 inhibitors higher in females [135]. The gene discussed is IL23A; the disease is psoriasis.